Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz
|Dr. Steven J. Mento Ph.D.||Co-Founder, CEO, Pres & Director||835.33k||N/A||65|
|Dr. Alfred P. Spada Ph.D.||Co-Founder, Chief Scientific Officer and Exec. VP of R&D||589.49k||N/A||59|
|Dr. David T. Hagerty M.D.||Exec. VP of Clinical Devel.||590.29k||N/A||62|
|Dr. Keith W. Marshall Ph.D., MBA||CFO, COO & Exec. VP||N/A||N/A||N/A|
|Mr. Mark F. Morris||Head of Biostatistics||N/A||N/A||N/A|
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.
Conatus Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.